The global juvenile macular degeneration (JMD) treatment market is projected to grow from $0.20 billion in 2024 to $0.55 billion by 2032, at a compound annual growth rate (CAGR) of 12.80% from 2025 to 2032. The market is driven by increasing research in pediatric eye health, advancements in gene therapy, CRISPR-based treatments, and AI in retinal imaging. Key segments include gene therapy, small molecules, biologics, cell therapy, anti-VEGF agents, neuroprotectants, devices, implants, combination regimens, diagnostics, and applications such as pediatric ophthalmology, hospitals, specialty clinics, clinical trials, and telemedicine. Major companies involved include Roche, Novartis, Regeneron Pharmaceuticals, Amgen, Alcon, Bayer Healthcare, Biogen, Merck & Co., Eli Lilly, Gilead Sciences, Axovant Gene Therapies, Genentech, AbbVie, Allergan, Eyenovia, Graybug Vision, Opthea, Spark Therapeutics, Apellis Pharmaceuticals, Acucela, Astellas Pharma, MacroGenics, Voyager Therapeutics. North America is the dominant region, while Europe is the fastest-growing. Market challenges include high treatment costs, regulatory delays, limited specialist availability, competition from alternative therapies, and patient adherence issues.

The global thyroid gland disorder treatment market is expected to grow at a steady rate of approximately 3% from 2022 to 2032, reaching a market size of around USD 3 billion by 2032. North America is projected to dominate the market due to rising disease prevalence, increased public awareness, earlier diagnosis, and strong investments in research and development. The market is segmented by drug type, disorder type, route of administration, and geography. Levothyroxine holds the largest market share in 2024. Key players include Pfizer Inc., AbbVie Inc., GSK plc, Merck & Co., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Amgen Inc., AstraZeneca, Amgen Inc., Hikma Pharmaceuticals PLC, Takeda Pharmaceutical Company Limited, Novartis AG, Exelixis, Inc., Sanofi, Viatris Inc., Provell Pharmaceuticals, LLC, IBSA Pharma Inc., Tourmaline Bio, Inc., Azurity Pharmaceuticals, Inc., and ADVANZ Pharma. Regulatory approvals, such as Amgen's 2024 approval of TEPEZZA® for thyroid eye disease in Japan, and product launches like Hikma's 2022 levothyroxine injection in the U.S., are shaping market dynamics. Growth is driven by rising disease incidence, improved diagnostics, and advancements in biologic therapies and personalized treatment approaches, though challenges like patient compliance and healthcare access disparities remain.

The global fibromyalgia treatment market was valued at USD 3.49 billion in 2024 and is projected to reach USD 5.16 billion by 2034, growing at a CAGR of 3.97% from 2025 to 2034. North America dominated the market in 2024 with a 54% market share, while the Asia Pacific region is expected to be the fastest-growing. Key treatments include FDA-approved drugs such as pregabalin (Lyrica), duloxetine (Cymbalta), and milnacipran (Savella), with pharmacologic therapies accounting for 55% of the market in 2024. The digital therapeutic segment is expected to grow at the highest CAGR. AI technology is advancing drug discovery, diagnosis, and personalized treatment plans by analyzing patient data. Major pharmaceutical companies such as Pfizer, Eli Lilly, Teva, Novartis, and Abbott are key players in the market, investing in R&D for new therapies and personalized medicine.

The global market for non-invasive brain trauma monitoring devices is projected to reach USD 32.19 billion by 2034, growing at a compound annual growth rate (CAGR) of 8.13% from 2025 to 2034. This growth is driven by the increasing demand for minimally invasive healthcare, the adoption of advanced technologies such as EEG, NIRS, and transcranial Doppler ultrasound, and the integration of artificial intelligence (AI) and machine learning (ML) for improved diagnostic accuracy and predictive analytics. Key end-users include hospitals, neurological centers, and other healthcare facilities, with hospitals dominating the market due to high volumes of traumatic brain injury (TBI) cases. The market is segmented by region, with North America leading currently, followed by Europe and Asia-Pacific, where the latter is expected to grow at the highest rate due to improving healthcare infrastructure and rising awareness. Challenges such as a shortage of trained professionals to operate these devices remain, and solutions include targeted training programs and AI-driven automation to reduce human error and enhance outcomes. The report analyzes market dynamics, competitive landscape, and key players including Natus Medical Inc., Philips Healthcare, Nihon Kohden Corporation, GE Healthcare, and others.

The Global RNA-Based Therapeutics and Vaccines Market is projected to grow from $18.5 billion in 2025 to $55.2 billion by 2033, reflecting a CAGR of 15.19%. The market is driven by rising demand for treatments in oncology, infectious diseases, and rare diseases, accelerated by advancements in mRNA, siRNA, and delivery technologies. Key players include Moderna, BioNTech, CureVac, Arcturus Therapeutics, Sanofi, Pfizer, AstraZeneca, and others. North America is the dominant and fastest-growing region. Market challenges include high production costs, cold chain requirements, regulatory uncertainty, and safety concerns. The report covers market segmentation by type, application, and region, and includes a PESTLE analysis to assess political, economic, social, technological, legal, and environmental factors influencing growth.